Last $13.25 USD
Change Today -0.12 / -0.90%
Volume 361.0K
INSM On Other Exchanges
As of 5:20 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

insmed inc (INSM) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/16/14 - $22.29
52 Week Low
08/12/14 - $11.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INSMED INC (INSM)

insmed inc (INSM) Related Bloomberg News

View More Bloomberg News

insmed inc (INSM) Related Businessweek News

No Related Businessweek News Found

insmed inc (INSM) Details

Insmed Incorporated, a biopharmaceutical company, focuses on developing and commercializing inhaled therapies for patients with serious lung diseases. Its lead product candidate is ARIKAYCE, an inhaled antibiotic treatment that delivers a proven and potent anti-infective directly to the site of serious lung infections. The company’s ARIKAYCE is in Phase II clinical trial for patients with lung infections caused by non-tuberculous mycobacteria (NTM) in the United States and Canada; and completed a Phase III clinical trial in Europe and Canada for cystic fibrosis (CF) patients who have lung infections caused by Pseudomonas aeruginosa. Insmed Incorporated was founded in 1999 and is headquartered in Monmouth Junction, New Jersey.

61 Employees
Last Reported Date: 03/6/14
Founded in 1999

insmed inc (INSM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $445.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $330.0K
General Counsel and Corporate Secretary
Total Annual Compensation: $149.9K
Special Advisor To Chief Executive Officer
Total Annual Compensation: $422.2K
Compensation as of Fiscal Year 2013.

insmed inc (INSM) Key Developments

Insmed Mulls Acquisitions

Insmed Incorporated (NasdaqGS:INSM) is looking for acquisitions. Insmed Incorporated has filed a follow-on equity offering in the amount of $80 million and intends to use the net proceeds from this offering to fund further clinical development of ARIKAYCEâ„¢, or liposomal amikacin for inhalation, to treat nontuberculous mycobacteria (NTM) lung disease patients and Pseudomonas aeruginosa lung infections in cystic fibrosis (CF) patients, to fund its efforts to obtain regulatory approvals and commercialize ARIKAYCE for NTM patients and Pseudomonas aeruginosa in CF patients, to invest in increased third-party manufacturing capacity in anticipation of possible commercial launch of ARIKAYCE in Europe and the United States, and the balance to fund working capital, capital expenditures, general research and development, and other general corporate purposes, which may include the acquisition or in-license of additional compounds, product candidates, technology or businesses.

Insmed Incorporated Announces Executive Changes

Insmed Incorporated announced Matthew Pauls, Chief Commercial Officer (CCO), will be leaving Insmed in August 2014 to become the Chief Executive Officer of a biopharmaceutical company based in Sweden and the U.S. Insmed plans to initiate a search to identify a new CCO. Lilia Arviza, PhD, recently joined Insmed in the newly created role of Vice President of Global Medical Affairs. Dr. Arviza is responsible for medical education, medical communication and oversight of grants, investigator initiated studies and the medical science liaison personnel. Gina Eagle, MD, was recently promoted to Vice President of Clinical Development. Dr. Eagle is responsible for designing and overseeing the clinical trials and development of the Company's product candidates. Kevin McDermott was recently promoted to Vice President of Global Market Access. Mr. McDermott is responsible for developing pricing strategies, creating a strong pharmacoeconomic foundation, and securing market access worldwide. Mr. McDermott has more than 14 years of senior leadership in market access.

Insmed Incorporated Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Capital Expenditure Guidance for the Second Half of 2014

Insmed Incorporated announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported operating loss of $22.816 million against $8.269 million a year ago. Loss before income taxes was $23.224 million against $8.854 million a year ago. Net loss and comprehensive loss was $23.224 million or $0.59 per diluted share against $8.854 million or $0.28 per diluted share a year ago. The increase in net loss was primarily due to $11.5 million in Other revenue received during the 2013 quarter related to a one-time payment for the sale of the Company's right to receive future royalties under its license agreement with Premacure (now Shire plc), as well as to higher expenses in the 2014 quarter. For the six months, the company reported operating loss of $40.895 million against $22.579 million a year ago. Loss before income taxes was $41.911 million against $23.753 million a year ago. Net loss and comprehensive loss was $37.522 million or $0.96 per diluted share against $22.532 million or $0.71 per diluted share a year ago. In the second half of 2014 the company expects to invest $2.5 million to $3.5 million in new capital expenditures and pay current liabilities of $2.5 million related to the company's new office and laboratory facilities in Bridgewater, N.J.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INSM:US $13.25 USD -0.12

INSM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INSM.
View Industry Companies

Industry Analysis


Industry Average

Valuation INSM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSMED INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at